PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE® antisense technology against influenza A and E. coli infection. The data was presented in two posters at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meetings held in San Francisco.
